ZNA Antwerpen   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Antwerp Belgium (2004)

Organization Overview

First Clinical Trial
2006
NCT00689000
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Nina Hermans | Stuyvenberg Hospital Antwerpen | Ziekenhuis Netwerk Antwerpen (ZNA) | ZNA Antwerpen, Antwerp, Belgium | ZNA Antwerpen, Belgium

Active Ingredients

Drugs in Phase 4 Trials (2)

olive (1 trial)

red yeast (1 trial)

Drugs in Phase 3 Trials (2)

raloxifene (evista) (1 trial)

semaglutide (Ozempic) (1 trial)

Drugs in Phase 2 Trials (5)

abatacept (orencia) (1 trial)

autologous mesenchymal stem cells (2 trials)

mycophenolate (CellCept) (1 trial)

sirolimus (rapamune) (2 trials)

tosedostat (1 trial)

Drugs in Other Trials (1)

furosemide (lasix) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Disease (Phase 3)

Eye Diseases (Phase 2)

Graft vs Host Disease (Phase 2)

Hodgkin Disease (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lymphoma, Non-Hodgkin (Phase 2)

Mental Disorders (Phase 3)

Multiple Myeloma (Phase 2)

Myelodysplastic Syndromes (Phase 2)

Myeloproliferative Disorders (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Precursor Cell Lymphoblastic Leukemia-Lymphoma (Phase 2)

Preleukemia (Phase 2)

Psychotic Disorders (Phase 3)

Schizophrenia (Phase 3)

Uveitis (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 10
  • # of Trial APIs: 10